Jiaxi Ding, MD
Ophthalmology · Winston Salem, NCNPI 1457648412
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,250 of the $12,956 with a category attached, or 86.8%. 15 manufacturers reported payments, led by Rxsight Inc at 52.8% of the total. 2025 is the largest year on record at $7,139, more than ten times the $45 reported in 2019. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $196.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$7K
- Sight Sciences, Inc.$5K
- AbbVie$326
- Alcon$211
- Johnson & Johnson Surgical Vision, Inc.$151
- Nova Eye, Inc.$127
- plus $392 from 9 others
Across 5 payments — averaging $6000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$30K
What the payments were for
- Consulting fees$11,25087%
- Speaking & faculty fees$280%
- Food & beverage$1,67813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 12 | $6,838 |
| Sight Sciences, Inc. | 10 | $4,912 |
| AbbVie(2 entities) | 12 | $326 |
| Alcon | 9 | $211 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $151 |
| Nova Eye, Inc. | 1 | $127 |
| NEW World Medical,inc. | 4 | $90 |
| Aerie Pharmaceuticals, Inc. | 2 | $67 |
| Oyster Point Pharma, Inc. | 2 | $53 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Glaukos Corporation | 2 | $40 |
| Amgen(2 entities) | 2 | $39 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| Thea Pharma Inc. | 1 | $20 |
| Ivantis, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,956 in reported general payments places this provider in the 90th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 197 | $90,088 |
| LumiganBimatoprost | 54 | $27,891 |
| RocklatanNetarsudil Mesylat/Latanoprost | 41 | $21,641 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 62 | $19,741 |
| Latanoprost | 825 | $9,575 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $7,914 |
| Prednisolone Acetate | 158 | $7,800 |
| ProlensaBromfenac Sodium | 20 | $7,088 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 578 | $6,599 |
| Methazolamide | 25 | $5,270 |
| VyzultaLatanoprostene Bunod | 14 | $4,577 |
| Brimonidine Tartrate | 359 | $3,580 |
| Travoprost | 20 | $3,560 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,528 |
| Apraclonidine Hcl | 20 | $2,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $67 | $111,729238 claims |
| AbbVieLumigan, Combigan | $326 | $35,80575 claims |
| AlconSimbrinza | $211 | $19,74162 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $40 | $4,57714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Winston Salem
- Rajiv ShahWinston Salem$909K
- Keith WalterWinston Salem$397K
- Vishak JohnWinston Salem$156K
- Charles RichardsWinston Salem$9K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.